Rchr
J-GLOBAL ID：201901016634353592
Update date: Oct. 27, 2024
Asatsuma Tomoko
Asatsuma Tomoko
Research field (1)：
Molecular biology
Research theme for competitive and other funds (2)：
- 2020 - 2022 Elucidation of the combination effects of HDAC inhibitors and IMiDs
- 2011 - 2012 ビタミンD受容体のユビキチンリガーゼ活性の分子機構解明
Papers (12)：
-
Masaaki Hashiguchi, Tomoko Asatsuma-Okumura, Yoshiko Iwai. Interleukin 21 promotes IgG1+ plasma cell differentiation instead of class switching to IgE via Blimp1 expression. European Journal of Immunology. 2024
-
Fumihiko Ando, Takeru Kashiwada, Shoko Kuroda, Takenori Fujii, Ryotaro Takano, Yoshishige Miyabe, Shinobu Kunugi, Takashi Sakatani, Akihiko Miyanaga, Tomoko Asatsuma-Okumura, et al. Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. Frontiers in pharmacology. 2024. 15. 1384731-1384731
-
Takeru Kashiwada, Ryotaro Takano, Fumihiko Ando, Shoko Kuroda, Yoshishige Miyabe, Ryuji Owada, Akihiko Miyanaga, Tomoko Asatsuma-Okumura, Masaaki Hashiguchi, Yoshikazu Kanazawa, et al. Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients. Frontiers in pharmacology. 2024. 15. 1384733-1384733
-
Takumi Ito, Tomoko Asatsuma-Okumura, Akinori Endo, Junichi Yamamoto, Yoshiko Iwai, Yuki Yamaguchi, Mikihiko Naito, Hiroshi Handa, Yasushi Saeki. ZNF276 and WIZ are CRBN neosubstrates involved in the anti-angiogenic activity of thalidomide and immunomodulatory drugs. 2023
-
Nobuyuki Shimizu, Tomoko Asatsuma-Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates. Communications biology. 2021. 4. 1. 1277-1277
ｍore...
MISC (11)：
-
朝妻知子, 岩井佳子, 半田宏, 伊藤拓水. サリドマイド及びその誘導体の血管新生阻害作用機構の解明. 日本生化学会大会(Web). 2023. 96th
-
Junichi Yamamoto, Tomoko Asatsuma-Okumura, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa. History of IMiDs and protein degradation as a pharmacological modality. Protein Homeostasis in Drug Discovery: A Chemical Biology Perspective. 2022. 285-315
-
朝妻知子, 伊藤拓水, 半田宏. HDAC阻害剤の抗骨髄腫作用に関する研究. 東京医科大学雑誌(Web). 2022. 80. 2
-
朝妻知子, 半田宏, 伊藤拓水. Development of new cereblon modulators and their target proteins. 月刊血液内科. 2022. 84. 4
-
朝妻知子, 伊藤拓水, 山口雄輝, 半田宏. Identification of CRL4CRBN neosubstrates involved in thalidomide teratogenicity. 日本農芸化学会大会講演要旨集(Web). 2021. 2021
ｍore...
Patents (1)：
Return to Previous Page
